Lorlatinib | List of Frontiers open access articles

Original Research

Published on 15 Feb 2024

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

in Health Economics

Wenjie Liu
Gengwei Huo
Peng Chen

Frontiers in Public Health

doi 10.3389/fpubh.2024.1213318

5,167 views
1 citation

Original Research

Published on 23 Aug 2021

A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier

in Drug Metabolism and Transport

Wei Chen
Chunyu Li
Yafei Shi
Yujun Zhang
Dujia Jin
Mingyu Zhang
Mingming Bo
Guohui Li

Frontiers in Pharmacology

doi 10.3389/fphar.2021.722627

5,033 views
5 citations

Original Research

Published on 05 Jun 2024

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system

in Pharmacoepidemiology

Huqun Li
Chongshu Wang
Cuilian Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385036

7,602 views
10 citations

Original Research

Published on 28 May 2021

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

SiNi Li
JianHe Li
LiuBao Peng
YaMin Li
XiaoMin Wan

Frontiers in Oncology

doi 10.3389/fonc.2021.684073

9,760 views
16 citations

Case Report

Published on 24 Feb 2023

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

in Neuro-Oncology and Neurosurgical Oncology

Shubin W. Shahab
Matthew Schniederjan
Jose Velazquez Vega
Stephen Little
Andrew Reisner
Tobey MacDonald
Dolly Aguilera

Frontiers in Oncology

doi 10.3389/fonc.2023.1123378

5,824 views
13 citations

Case Report

Published on 23 Mar 2026

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report

in Pediatric Oncology

Sultan Aydin
Ayse Oz

Frontiers in Oncology

doi 10.3389/fonc.2026.1790294

558 views
1 citation

Case Report

Published on 26 Jan 2024

Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report

in Thoracic Oncology

Ruiqi Niu
Yiruo Zhang
Jingdan Pang
Qing Zhou
Yu Lei
Yingying Du

Frontiers in Oncology

doi 10.3389/fonc.2024.1341233

3,556 views
2 citations

Original Research

Published on 01 May 2025

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

in Thoracic Oncology

Guangming Tian
Jun Nie
Ling Dai
Weiheng Hu
Jie Zhang
Di Wu
Xiangjuan Ma
Xiaoling Chen
Sen Han
Jindi Han

Frontiers in Oncology

doi 10.3389/fonc.2025.1577607

5,361 views
7 citations

Case Report

Published on 29 Aug 2024

Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review

in Thoracic Oncology

Zijun Xu
Xiaofeng Cong
Ziling Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1415254

2,020 views

Case Report

Published on 05 Mar 2024

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia

in Cardio-Oncology

Lukas Mayer-Suess
Michael Knoflach
Andreas Pircher
Stefan Kiechl
Christoph Schmidauer
Eva Hametner

Frontiers in Oncology

doi 10.3389/fonc.2024.1322501

2,560 views
2 citations

Original Research

Published on 09 May 2025

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

in Pharmacology of Anti-Cancer Drugs

Vera Damuzzo
Lorenzo Gasperoni
Luna Del Bono
Andrea Ossato
Alessandro Inno
Andrea Messori

Frontiers in Oncology

doi 10.3389/fonc.2025.1566816

7,922 views
5 citations

Case Report

Published on 31 Jul 2024

A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement

in Pharmacology of Anti-Cancer Drugs

Yang Zheng
Fanfei Zhao
Yaqian Ren
Yaran Xue
Bing Yan
Chun Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1401428

2,508 views
4 citations

Case Report

Published on 31 Oct 2022

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment

in Molecular and Cellular Oncology

Xugang Zhang
Baoming Wang
Chunyang Wang
Chengde Liao
Shiping Wang
Ran Cao
Tonghui Ma
Kun Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.1021342

4,918 views
7 citations

Original Research

Published on 23 Dec 2021

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase

in Molecular and Cellular Oncology

Shuai Liang
Qing Wang
Xuesen Qi
Yudi Liu
Guozhen Li
Shaoyong Lu
Linkai Mou
Xiangyu Chen

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.808864

5,733 views
19 citations

Original Research

Published on 21 Sep 2022

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

in Health Economics

Xia Luo
Zhen Zhou
Xiaohui Zeng
Liubao Peng
Qiao Liu

Frontiers in Public Health

doi 10.3389/fpubh.2022.985834

11,067 views
17 citations

Original Research

Published on 17 Mar 2022

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study

in Drugs Outcomes Research and Policies

Yihan Liu
Chen Chen
Chencheng Rong
Xucheng He
Li Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2022.858279

8,669 views
38 citations

Articles

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report

Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study